Welcome to our dedicated page for Cyclacel Pharma news (Ticker: CYCC), a resource for investors and traders seeking the latest updates and insights on Cyclacel Pharma stock.
Cyclacel Pharmaceuticals (CYCC) is a clinical-stage biopharmaceutical company pioneering targeted cancer therapies through cell cycle regulation. This resource provides investors and researchers with timely updates on clinical developments, regulatory milestones, and strategic initiatives.
Access comprehensive coverage of CYCC's progress with its CDK and PLK inhibitor pipeline, including fadraciclib and plogosertib development. Stay informed about critical updates across multiple news categories: clinical trial results, regulatory filings, research collaborations, and intellectual property developments.
Our curated news collection enables efficient tracking of the company's precision medicine approach and therapeutic innovations in oncology. Regular updates ensure you never miss pivotal announcements about trial phases, partnership agreements, or scientific presentations.
Bookmark this page for streamlined access to verified CYCC developments. Check back frequently for objective reporting on advancements in targeted cancer treatment research and their implications for hematology/oncology care.
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, CYCCP) will announce its first quarter 2022 financial results on May 11, 2022. A conference call and live webcast will take place at 4:30 p.m. EDT on the same day. Cyclacel specializes in developing innovative cancer medicines targeting cell cycle and transcriptional regulation. Their current projects include fadraciclib, a CDK2/9 inhibitor, and CYC140, a PLK1 inhibitor, aimed at treating solid tumors and hematological malignancies. The webcast will be available for 90 days after the event.
Cyclacel Pharmaceuticals has commenced a multi-cohort Phase 1/2 study for CYC140, a potent PLK1 inhibitor, targeting advanced solid tumors and lymphomas. The first patient has been dosed, with trials set to evaluate safety, tolerability, and efficacy. Initial data are expected in H1 2023. The trial, CYC140-101, aims to establish an optimal dosing regimen and will involve various cancer types, including those with specific genetic mutations. CYC140 shows promise in preclinical studies, indicating potential new treatment options for resistant cancer types.
Cyclacel Pharmaceuticals announced significant preclinical data for its CDK2/9 inhibitor fadraciclib, which demonstrates its potential in treating chronic lymphocytic leukemia (CLL) and synergy with venetoclax.
Research from the University of Texas MD Anderson shows fadraciclib reduces anti-apoptotic protein MCL1 and induces apoptosis, particularly in 17p deleted CLL cells. These findings support ongoing Phase 1/2 clinical trials for fadraciclib in combination therapies. The company aims to enhance treatment options for patients resistant to current therapies.
Cyclacel Pharmaceuticals reported its financial results for Q4 and full year 2021, showing a net loss of $18.9 million, up from $8.4 million in 2020. Cash equivalents increased to $36.6 million, projected to last through mid-2023. The Phase 1/2 study of fadraciclib in solid tumors is ongoing, with initial data expected in the first half of 2022. The company is also initiating a Phase 1/2 study for oral CYC140. Key clinical milestones are anticipated throughout 2022, supporting its position as a contender in cancer treatment.
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, CYCCP) will announce its fourth quarter and full year 2021 financial results on March 28, 2022. A conference call and live webcast are scheduled for 4:30 p.m. EDT on the same day. The call can be accessed through U.S./Canada and international lines. Cyclacel is focused on developing innovative cancer medicines, including fadraciclib and CYC140. The company emphasizes a diversified pipeline and ongoing research in oncology and hematology to address critical medical needs.
Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) announced its participation in the 32nd Annual Oppenheimer Healthcare Conference. Management will present on the Targeted Oncology Panel on March 14, 2022, at 10:00 AM ET in a fireside chat format. Additionally, the company will have a separate presentation on March 17, 2022, from 12:40 PM to 1:10 PM ET. Both sessions will be accessible via registration links, and replays will be available for 90 days. Cyclacel focuses on developing innovative cancer treatments based on cell cycle and transcriptional regulation.
Cyclacel Pharmaceuticals announced its participation in the 2022 BIO CEO & Investor Conference from February 14-17, 2022. The event will include 1-on-1 virtual meetings with senior management and an on-demand presentation available from February 11, 2022. Cyclacel focuses on developing innovative cancer medicines, including fadraciclib, a CDK2/9 inhibitor, and CYC140, a PLK1 inhibitor. Interested parties can access the presentation on Cyclacel's website for 90 days post-conference.
Cyclacel Pharmaceuticals provided a business update on January 6, 2022, highlighting its achievements in 2021 and objectives for 2022. The company initiated two registration-directed trials for its lead candidate, oral fadraciclib, an oral CDK2/9 inhibitor, aiming to address solid tumors and hematological malignancies. Additionally, they received FDA clearance for a Phase 1/2 study of CYC140, a PLK1 inhibitor. Cyclacel raised $14.5 million in early 2021, ensuring financial stability until early 2023, with key data readouts expected in 2022.
Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) announced participation in the Biotech Showcase 2022 Virtual Conference on January 10-12, 2022. CEO Spiro Rombotis will present an overview of the company and engage in virtual meetings. He will also lead a workshop titled “Outsmarting Cancer: Next Generation Therapies” on January 10 at 8:00 AM PT/11:00 AM ET. The conference presentation and archived webcast will be accessible on the company’s website for 90 days after January 3, 2022, enhancing investor insight into Cyclacel's innovative cancer therapies.
Cyclacel Pharmaceuticals reported its Q3 2021 financial results, highlighting ongoing clinical studies for fadraciclib and CYC140. The company is currently enrolling patients in two Phase 1/2 studies for fadraciclib in leukemia and advanced solid tumors. As of September 30, 2021, Cyclacel had $40.2 million in cash, projecting a runway through early 2023. R&D expenses rose to $4.2 million from $1.1 million in Q3 2020, primarily due to increased clinical trial activities. The net loss for the quarter was $5.0 million, up from $2.3 million in the same period last year.
